85 results
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
14 May 24
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:10pm
for Medicare and Medicaid Services (CMS) in March for the OneRF™ ablation procedure to support accurate data collection and processing of reimbursement … : the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
26 Mar 24
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
9:20am
funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
15 Mar 24
Submission of Matters to a Vote of Security Holders
4:30pm
or adequate reimbursement for our technology ; uncertainties inherent in the development process of our technology ; risks related to changes in regulatory … Management. Prior to CSI, Mr. Volker held executive leadership roles at St. Jude Medical where he led Corporate Development, Health Economics & Reimbursement
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
13 Feb 24
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:15pm
ablation procedure, to support accurate data collection and processing of reimbursement claims by hospitals for the ablation procedure
Presented … and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology
8-K
EX-99.1
ajiie gr217gb94
14 Dec 23
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-99.1
uq8b93reabaxawrab
11 Dec 23
NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System
8:15am
8-K
EX-99.1
ubxt0nrhiy
16 Nov 23
NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
8:00am
8-K
EX-99.1
0fp68krw y1j8jl6aqm
14 Nov 23
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement
5:28pm
8-K
l47pawwq
14 Nov 23
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement
5:28pm
8-K
EX-99.1
agaq5rnej98p8
7 Nov 23
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
8:15am
8-K
EX-99.1
8u8lxag
14 Aug 23
NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
4:15pm
8-K
EX-1.1
w21c9y2j7zz1av
27 Jul 23
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock
4:02pm
424B5
umjie 4ua3
26 Jul 23
Prospectus supplement for primary offering
4:24pm
424B5
ttkooxx opf
24 Jul 23
Prospectus supplement for primary offering
4:43pm